After upstaging Merck & Co.’s Keytruda as a monotherapy for patients with first-line non-small cell lung cancer (NSCLC) in ...

More than two years after a positive topline readout, AstraZeneca has to face the reality that a lack of an overall survival ...

In the first opportunity for industry watchers to compare the two approved TROP2 antibody-drug conjugates side by side in ...

Merck’s efforts to make headway in a cancer type that was an elusive target for its superstar oncology med Keytruda prove to ...

Six years since the FDA blessed Sanofi and Regeneron’s Dupixent as the first biologic to treat chronic rhinosinusitis with ...

The discounted access to Xofluza comes as the U.S. flu season begins. Genentech pointed to CDC data showing that last year’s ...

For years, MASH was where drug development dreams went to die.  | After Rezdiffra’s approval and Wegovy’s label expansion, ...

Sanofi gained Rezurock in a $1.9 billion buyout of Kadmon in 2021, less than two months after the FDA approved the treatment ...

Dianthus Therapeutics and Boehringer Ingelheim headlined the latest round of licensing d | Dianthus and Boehringer Ingelheim ...

Now four years into a first-in-class FDA approval for certain HR-positive, HER2-negative early breast cancers, Eli Lilly’s ...

Results presented by AstraZeneca from its phase 3 trial of Imfinzi in patients with high-risk, non-muscle invasive bladder ...

Even after Merck & Co.’s Keytruda has climbed to the top of the industry’s sales charts and racked up dozens of FDA-a | A ...